News

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...
Once-daily oral treatment for obesity that mimics metabolic effects of gastric bypass shows promise in study
A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrates positive ...
TCTMD41m
Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...
The ‘particularly alarming’ ways that obesity affects teenage brains revealed in new study
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...
Session finale, obesity rankings, celeb golfers: Down in Alabama
Alabama has moved up the most recent obesity rankings from U.S. News & World Report. And we’re getting awfully close to the ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Explore more
STAT6h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Mass. residents who take GLP-1 drugs for obesity tend to be white and affluent. But who needs them most?
The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...
Greater risk of overweight, obesity among preschoolers living in rural areas linked to more sedentary, screen time
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals that 3 to ...